A Long-term Access Programme for Subjects With Severe Asthma

Inclusion Criteria:

• Subject participated in GSK-sponsored asthma clinical study with mepolizumab asspecified in Study 200862 and 200363

• Subject has either: completed the treatment period in the mepolizumab asthma clinicalstudy to which they were originally enrolled or if the subject was withdrawn fromstudy treatment prematurely during the mepolizumab asthma clinical study to whichthey were originally enrolled but the subject has completed the study assessments atthe study visit that would have been the end of the respective treatment period.

• The treating physician requesting mepolizumab under this Long-term Access Programmeconsiders the benefits of treatment with mepolizumab outweigh the risks for theindividual subject.

• To be eligible for mepolizumab treatment under this Long-term Access Programme,females of childbearing potential (FCBP) must commit to consistent and correct use ofan acceptable method of birth control, beginning with consent, for the duration ofthe treatment with mepolizumab and for 4 months after the last mepolizumabadministration.

• The subject consents to receiving treatment with mepolizumab under this Long-termAccess Programme. In the case of a paediatric subject being eligible aparent(s)/guardian will give written informed consent prior to the child'sparticipation in the study. If applicable, the subject must be able and willing togive assent to take part in the study according to the local requirement.

Exclusion Criteria:

• A current malignancy or history of cancer in remission for less than 12 months (Subjects who had localized carcinoma (i.e., basal or squamous cell) of the skinwhich was resected for cure will not be excluded).

• Subject has other clinically significant medical conditions uncontrolled withstandard-of-care therapy not associated with asthma, e.g., unstable liver disease,uncontrolled cardiovascular disease, ongoing active infectious disease requiringsystemic treatment.

• Subject is pregnant or breastfeeding. Subjects should not be considered for continuedtreatment if they plan to become pregnant during the course of treatment withmepolizumab.

• Subject has a known allergy or intolerance to a monoclonal antibody or biologictherapy including mepolizumab.

• Subject had an adverse event (serious or non-serious) considered related to studytreatment whilst participating in a clinical study with mepolizumab which resulted inpermanent withdrawal of study treatment.

• Subject is receiving treatment with another biological therapy such as a monoclonalantibody therapy or intravenous (IV) immunoglobulin (Ig) therapy.

• Subjects who have received treatment with an investigational drug within the past 30days or 5 terminal phase half-lives of the drug whichever is longer, prior toinitiation of mepolizumab treatment under this Long-term Access Programme (this alsoincludes investigational formulations of marketed products).

• Subject is currently participating in any other interventional clinical study.